Amicogen Inc

Amicogen Inc operates with a capital structure that shows a debt-to-equity ratio of 1.03, indicating a relatively balanced mix of debt and equity financing. The company's liquidity position is characterized by a current ratio of 0.83, suggesting that its current liabilities exceed its current assets, which could pose a short-term liquidity risk. The company's cash and equivalents amount to KRW 21,930.5 million, but this is significantly lower than its long-term debt of KRW 178,001.6 million, resulting in a negative net cash position.

In terms of profitability, Amicogen is currently unprofitable, with a net loss of KRW 5,545.9 million and an operating loss of KRW 2,962.9 million. The company's return on equity (ROE) is -3.19%, and its return on assets (ROA) is -1.13%, both of which are below the industry median for biotechnology firms, indicating underperformance relative to its peers.

Amicogen's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification could expose the company to higher operational and market risks, particularly in the event of regulatory changes or market downturns in its primary operating region.

The company's growth trajectory is currently constrained by its negative operating and free cash flows, which are -KRW 320.5 million and -KRW 22,847.6 million, respectively. Capital expenditures of -KRW 20,696.9 million indicate significant investment in infrastructure or R&D, but without corresponding revenue growth, this could further strain the company's financial position.

Amicogen's risk profile is marked by medium liquidity risk and low dilution potential, as per the risk assessment. The company's negative net cash position after subtracting total debt is a key flag, suggesting potential challenges in meeting long-term obligations without additional financing. No recent events or filings have been disclosed in the available data that would indicate significant changes in the company's strategic or financial direction.

The company's recent financial performance and capital structure suggest a need for careful monitoring of its liquidity and profitability trends. The absence of disclosed recent events or strategic shifts implies that the company's current challenges are likely to persist unless significant operational or financial improvements are made.

Operating and net margins rank in the top quartile compared to the biotechnology cohort median.

Return on equity exceeds the cohort median, indicating relatively better capital efficiency than peers.

Free cash flow improved significantly year-over-year, reducing the cash burn rate compared to the prior period.

Dilution risk is assessed as low, suggesting limited immediate threat to shareholder equity value.

Gross profit remained positive in the latest period, demonstrating some ability to generate margin on sales.

The company faces high credit risk, indicating significant concerns regarding its ability to meet debt obligations.

Debt-to-equity ratio is 1.03, placing it in the bottom quartile compared to the biotechnology cohort.

Cash conversion is in the bottom quartile of the cohort, highlighting poor efficiency in generating cash from operations.

Revenue KRW 144.30B, +15,6% YoY; Operating income −13,6% YoY.

• ▍Revenue KRW 144.30B, +15,6% YoY
• ▍Operating income −13,6% YoY
• ▍Net income −1 365,0% YoY
• ▍Free cash flow −93,0% YoY
• ▍Net margin -32.7%

Revenue KRW 124.88B; Operating income -KRW 7.75B.

• ▍Revenue KRW 124.88B
• ▍Operating income -KRW 7.75B
• ▍Net margin 3.0%